Entecavir;Entecavir

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 7, 2008, Pages 39-48

  Calleja, José Luis ^a   Peñas, Beatriz ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Entecavir; Lamivudine; Resistance; Viral supresi n

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS E ANTIGEN; LAMIVUDINE; ADEFOVIR DIPIVOXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; HEPATITIS B(E) ANTIGEN; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; REVIEW; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TRANSPLANTATION; MULTICENTER STUDY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

ADENINE; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MULTICENTER STUDIES AS TOPIC; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 67649222382     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76518-2     Document Type: Article

References (37)

1. C.J. Chen, H.I. Yang, and J. Su Risk of hepatocellular carcinoma across a biological gradient of serum Hepatitis B Virus DNA level JAMA 295 2006 65 73 (Pubitemid 43042691)
2. U.H. Iloeje, H.I. Yang, C.L. Jen, et al. Predicting chirrosis risk base on the level of circulating hepatitis B viral load Gastroenterol 130 2006 678 686
3. U.H. Iloeje, H.I. Yang, C.L. Jen, et al. Risk and predictors of mortality associates with chronic hepatitis B virus infection: the REVEAL Study Clin Gastroenterol Hepatol 5 2007 921 931
4. D. Robinson, L. Scott, and G. Plosker Entecavir, a review of its use in chronic hepatitis B Drugs 66 2006 1605 1622 (Pubitemid 44376345)
5. T.T. Chang, R.G. Gish, and S.J. Hadzyannis A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients Gastroenterol 129 2005 1198 1209 (Pubitemid 41446860)
6. E. Keefe, S. Zeuzem, and R. Koff Report of an International Workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin Gastroenterol Hepatol 5 2007 890 897 (Pubitemid 47127032)
7. J. Matthews Entecavir for the treatment of chronic hepatitis B virus infection Clin Ther 28 2006 184 203
8. R.A. De Man, L.M.M. Wolters, and F. Nevens Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection Hepatology 34 2001 578 582 (Pubitemid 32786650)
9. C.L. Lai, M. Rosmawatti, and J. Lao Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection Gastroenterol 123 2002 1831 1838 (Pubitemid 35408307)
10. G. Yao, D. Xu, B. Wang, et al. A phase II study in China of the safety and antiviral activity of entecavir in adults with chronic hepatitis B infection Hepatology 38 Suppl 4 2003 711A
11. G. Yao, X. Zhou, D. Xu, et al. A randomized placebo-controlled study (ETV-56) in China of the efficacy and safety of entecavir in chronic hepatitis B patients who have failed lamivudine Hepatology 40 Suppl. 1 2004 674A
12. T.T. Chang, R.G. Gish, and R. De Man A comparision of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010 (Pubitemid 43357804)
13. C.L. Lai, D. Shouval, and A.S. Lok Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020 (Pubitemid 43357805)
14. G. Yao, C. Chen, W. Lu, et al. Entecavir is superior to lamivudine for the treatment of chronic hepatitis B: results of phase III Chinese study (ETV-023) in nucleoside-naives patients [abstract no. 519 plus poster] J Hepatol 44 Suppl 2 2006 S193
15. R.G. Gish, P.M. Chang, R.A. De Man, et al. Entecavir results in substancial virologic and biochemical response and HBeAg seroconversion through 96 weeks of treatment in HBeAg-positive chronic hepatitis B patients Hepatology 42 Suppl 1 2005 267A
16. M. Rowasmati, E. Schiff, R. Parana, et al. Entecavir is superior to lamivudine at reducing HBV DNA in patients with chronic hepatitis B regardless of baseline alanine aminotransferase levels Hepatology 40 Suppl 1 2004 656A
17. F. Poordad, D.T. Dieterich, A.D. Min, et al. Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg-negative chronic hepatitis B patients Gastroenterol 130 Suppl 2 2006 848
18. T.T. Chang, Y.C. Chao, S. Kaymakoglu, et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naïve HBeAg-positive patients (ETV 022/901) Hepatology 44 Suppl 1 2006 229A
19. R. Gish, T.T. Chang, R. De Man, et al. Hepatitis B surface antigen loss in antiviral-treated patients with HBe Ag-postive chronic hepatitis B infection: observations from antiviral-naïve patients treated with entecavir or lamivudine Hepatology 44 Suppl 1 2006 558A
20. N. Leung, C.Y. Peng, J. Sollano, et al. Entecavir results in higher HBV DNA reduction vs. Adefovir in chronically infected HBe Ag-positive antiviral- naïve adults: 24 wk results (E.A.R.L.Y study) Hepatology 44 Suppl 1 2006 554A
21. G. Yao, C.W. Chen, W. Lu, et al. Entecavir achieves superior virologic response compares to Lamivudine for the treatment of chronic hepatitis B: 2-years results for a phase III study in nucleoside-naïve patients in China (ETV-023) Hepatology 44 Suppl 1 2006 559A
22. G. Yao Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China J Antimicrob Chemother 60 2007 201 205 (Pubitemid 47243868)
23. T.T. Chang, Y.C. Chao, J. Solano, et al. Entecavir treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg (+) chronic hepatitis B patients J Gastroenterol Hepatol 21 2006 A88 A92
24. D. Shouval, U.S. Akarca, G. Hatzis, et al. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBe Ag (-) chronic hepatitis B patients Hepatology 44 Suppl 2 2006 S21
25. M. Sherman, C. Yurdaydin, and J. Sollano Entecavir for treatment of lamivudine-refrectory, HBeAg-positive chronic hepatitis B Gastroenterol 130 2006 2039 2049 (Pubitemid 43816960)
26. C. Yuraydin, J. Sollano, S.J. Hadzyannis, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversión through 96 weeks of treatment in lamivudine-refractory HBeAg-positive chronic hepatitis B patients J Hepatol 44 Suppl 2 2006 s36
27. G. Yao, X. Zhou, D. Xu, et al. Entecavir results in early viral load reduction in chronic hepatitis B patients who failed lamivudine therapy: a randomized placebo-controlled study in China J Hepatol 44 Suppl 2 2006 S193
28. H. Simsek, E. Schiff, Z. Goodman, et al. Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection: results of three pivotal trials J Hepatol 44 Suppl 2 2006 S191
29. W. Pessoa, B. Gazzard, A. Huang, et al. Entecavir in HIV-HBV-co-infected patients: safety and efficacy in phase II study (ETV-038) 12 th Conference on retroviruses and oppornunistic infection Boston, Feb 22-25 2005
30. M.A. McMahon, B.L. Jilek, T.P. Brennan, et al. The HBV drug entecavir- effects on HVI-1 replication and resistance N Engl J Med 356 2007 2614 2621
31. A.O. Shakil, L. Lilly, P. Angus, et al. Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for chronic hepatitis B infection J Hepatol 36 Suppl 1 2002 122
32. R.J. Colonno, R.E. Rose, S.M. Levine, et al. Entecavir resistance is not observed in nucleotide-naïve subjets and is observed infrequently by 48 weeks in lamivudine-refractory subjets with chronic HBV infection J Hepatol 42 Suppl 2 2005 173S
33. D.J. Tenney, S.M. Levine, R.E. Rose, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistance to lamivudine Antimicrob Agents Chemother 48 2004 3498 3507
34. R.J. Colonno, R.E. Rose, K. Pokornowski, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine-refractory patients Hepatology 44 Suppl 1 2006 229A
35. S.K. Ono, N. Kato, and Y. Shiratori The polimerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance J Clin Invest 107 2001 449 455 (Pubitemid 32167991)
36. M.N. Brunelle, A.C. Jacquard, and C. Pichoud Susceptibility to antivirals of a human HBV strain with mutat¡ions conferring resistance to both lamivudine and adefovir Hepatology 41 2005 1391 1398 (Pubitemid 40770292)
37. J. Sollano, E. Schiff, F. Carrilho, et al. Entecavir is well-tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naïve and lamivudine-refractory patients Hepatology 40 Suppl 1 2004 A665